Kerry Flom - Cepheid Chief Regulatory Officer and Executive VP

EVP

Dr. Kerry J. Flom Ph.D. is Executive Vice President Chief Regulatory Officer of Cepheid since 2013.
Age 62
Tenure 11 years
Professional MarksPh.D
Phone408 541-4191
Webwww.cepheid.com
Flom was promoted to Executive Vice President, Chief Regulatory Officer in January 2013, and was Senior Vice President, Clinical Affairs & Regulatory Submissions from January 2010 until December 2012, after having joined us in May 2004 as Vice President, Clinical Affairs & Regulatory Submissions. Prior to joining company, Dr. Flom was Senior Director, Clinical Affairs and Regulatory Submission for Abbott Molecular Diagnostics from 2001 to 2004. Prior to Abbott, Dr. Flom directed the clinical affairs departments at Vysis, Inc., Baxter Health Corporationration – Cardiovascular Group, and Oncor, Inc. Before joining Oncor, Dr. Flom held clinical and R&D positions at Boehringer Mannheim Corporationration, Behring Diagnostics, and Corning Corporationrationrationration.

Cepheid Management Efficiency

The company has return on total asset (ROA) of (0.0746) % which means that it has lost $0.0746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.6296) %, meaning that it created substantial loss on money invested by shareholders. Cepheid's management efficiency ratios could be used to measure how well Cepheid manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 281.63 M in liabilities with Debt to Equity (D/E) ratio of 0.76, which is about average as compared to similar companies. Cepheid has a current ratio of 4.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cepheid until it has trouble settling it off, either with new capital or with free cash flow. So, Cepheid's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cepheid sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cepheid to invest in growth at high rates of return. When we think about Cepheid's use of debt, we should always consider it together with cash and equity.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and nonclinical markets. Cepheid (CPHD) is traded on NASDAQ Exchange in USA and employs 1,700 people.

Management Performance

Cepheid Leadership Team

Elected by the shareholders, the Cepheid's board of directors comprises two types of representatives: Cepheid inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cepheid. The board's role is to monitor Cepheid's management team and ensure that shareholders' interests are well served. Cepheid's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cepheid's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Gutshall, Co-Founder, Director, Member of Nominating and Governance Committee and Member of Compensation and Organizational Devel. Committee
Robert Easton, Independent Director
Glenn Steele, Independent Director
Thomas Brown, Independent Director
Warren Kocmond, COO and Executive VP
Jacquie Ross, IR Contact Officer
Kerry Flom, Chief Regulatory Officer and Executive VP
Daniel Madden, Vice President Corporate Controller and Acting CFO
Michael Fitzgerald, Executive VP of Global HR
Peter Farrell, Executive VP of Worldwide Commercial Operations
David Persing, Executive Vice President Chief Medical and Technology Officer, Director
Scott Campbell, Corporate Vice President , Chief Regulatory Officer
Marc Haugen, Executive Vice President - Engineering and Operations
John Bishop, Chairman, CEO and Member of Equity Incentive Committee
Cristina Kepner, Lead Independent Director
Hollings Renton, Independent Director
Joseph Smith, Executive Vice President - Corporate Development, General Counsel

Cepheid Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cepheid a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Cepheid

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cepheid position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cepheid will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Capital One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capital One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capital One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capital One Financial to buy it.
The correlation of Capital One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capital One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capital One Financial moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capital One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
Note that the Cepheid information on this page should be used as a complementary analysis to other Cepheid's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Cepheid Stock

If you are still planning to invest in Cepheid check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cepheid's history and understand the potential risks before investing.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Bonds Directory
Find actively traded corporate debentures issued by US companies
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments